Prevalence and management of drug interactions between nonsteroidal anti‐inflammatory drugs and antithrombotics in ambulatory care
Concomitant use of nonsteroidal anti‐inflammatory drugs (NSAIDs) and antithrombotic agents is associated with increased risks of both bleeding and thromboembolism. In this prospective intervention study, community pharmacists screened for NSAID‐antithrombotic interactions and contacted the prescribing physician to discuss interaction management. We included 782 interactions; these were found in an older, polymedicated patient population (mean age: 68 y, median of 5 other drugs). Ibuprofen (in 43.0% of cases) and low‐dose aspirin (78.8%) were the most frequently involved NSAID and antithrombotic, respectively. Anticoagulants were involved in 16.1% of interaction cases. For 61% of cases, the interacting drugs were prescribed by the same physician. The pharmacist–physician discussion about how to manage the interaction mostly resulted in no change of pharmacotherapy (60.7%); the most frequent reason given by physicians was that the NSAID was for short‐term use only. In 39.3% of cases the discussion resulted in a pharmacotherapy change; replacing the NSAID by paracetamol was the most common change..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:88 |
|---|---|
| Enthalten in: |
British Journal of Clinical Pharmacology - 88(2022), 8, Seite 3896-3902 |
| Beteiligte Personen: |
Mehuys, Els [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2022 The British Pharmacological Society |
|---|
| Umfang: |
7 |
|---|
| doi: |
10.1111/bcp.15288 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY002631253 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY002631253 | ||
| 003 | DE-627 | ||
| 005 | 20230307120850.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230213s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/bcp.15288 |2 doi | |
| 028 | 5 | 2 | |a BCP_BCP15288.xml |
| 035 | |a (DE-627)WLY002631253 | ||
| 035 | |a (WILEY)BCP15288 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.38 |2 bkl | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Mehuys, Els |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevalence and management of drug interactions between nonsteroidal anti‐inflammatory drugs and antithrombotics in ambulatory care |
| 264 | 1 | |c 2022 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2022 The British Pharmacological Society | ||
| 520 | |a Concomitant use of nonsteroidal anti‐inflammatory drugs (NSAIDs) and antithrombotic agents is associated with increased risks of both bleeding and thromboembolism. In this prospective intervention study, community pharmacists screened for NSAID‐antithrombotic interactions and contacted the prescribing physician to discuss interaction management. We included 782 interactions; these were found in an older, polymedicated patient population (mean age: 68 y, median of 5 other drugs). Ibuprofen (in 43.0% of cases) and low‐dose aspirin (78.8%) were the most frequently involved NSAID and antithrombotic, respectively. Anticoagulants were involved in 16.1% of interaction cases. For 61% of cases, the interacting drugs were prescribed by the same physician. The pharmacist–physician discussion about how to manage the interaction mostly resulted in no change of pharmacotherapy (60.7%); the most frequent reason given by physicians was that the NSAID was for short‐term use only. In 39.3% of cases the discussion resulted in a pharmacotherapy change; replacing the NSAID by paracetamol was the most common change. | ||
| 700 | 1 | |a De Backer, Tine |4 aut | |
| 700 | 1 | |a De Keyser, Filip |4 aut | |
| 700 | 1 | |a Christiaens, Thierry |4 aut | |
| 700 | 1 | |a Van Hees, Thierry |4 aut | |
| 700 | 1 | |a Demarche, Sophie |4 aut | |
| 700 | 1 | |a Van Tongelen, Inge |4 aut | |
| 700 | 1 | |a Boussery, Koen |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British Journal of Clinical Pharmacology |g 88(2022), 8, Seite 3896-3902 |w (DE-627)WLY00261751X |x 13652125 |7 nnns |
| 773 | 1 | 8 | |g volume:88 |g year:2022 |g number:8 |g pages:3896-3902 |g extent:7 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.38 |q ASE |
| 936 | b | k | |a 44.40 |q ASE |
| 951 | |a AR | ||
| 952 | |d 88 |j 2022 |e 8 |h 3896-3902 |g 7 | ||